Global Colony Stimulating Factors Market, By Type (Macrophage–Colony-Stimulating Factor (M-Colony Stimulating Factors), Multiple-Colony-Stimulating Factor, or Interleukin 3 (IL-3), Granulocyte-Macrophage–Colony-Stimulating Factor (GM-Colony Stimulating Factors), Granulocyte–Colony-Stimulating Factor (G-Colony Stimulating Factors)), Drug (Pegfilgrastim, Tbo-filgrastim, Sargramostim, Filgrastim), Application (Aplastic Anemia, Bone Marrow Transplantation, Neutropenia, Neutropenia Associated with Chemotherapy, Neutropenia Associated with Radiation, Peripheral Progenitor Cell Transplantation), Dosage (Tablets, Capsule, Injection, Others), Route of Administration (Intravenous, Subcutaneous, Oral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Colony Stimulating Factors Market Analysis and Size
Colony stimulating factors (Colony Stimulating Factors) are hormone-like proteins that promote the creation of immune cells that fight infections. Colony stimulating factors are produced by a variety of cells in our bodies and can travel throughout the body, binding to cells with specialized colony stimulating factors receptors. Colony stimulating factors are used as drugs to promote the formation of white blood cells because they can stimulate the synthesis of immune cells. For those whose immune systems have been decimated by chemotherapy or certain immunodeficiency illnesses, this could be a life-saving treatment. Colony stimulating factors are also significant drugs utilized in the transplantation of blood stem cells.
Data Bridge Market Research analyses that the colony stimulating factors market which was USD 7.72 billion in 2022, would rocket up to USD 17.42 billion by 2030, and is expected to undergo a CAGR of 10.70% during the forecast period.. “Bone marrow transplantation” dominates the application segment of the colony stimulating factors market due to the frequent need for bone marrow transplantation for various chronic diseases.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Macrophage–Colony-Stimulating Factor (M-Colony Stimulating Factors), Multiple-Colony-Stimulating Factor, or Interleukin 3 (IL-3), Granulocyte-Macrophage–Colony-Stimulating Factor (GM-Colony Stimulating Factors), Granulocyte–Colony-Stimulating Factor (G-Colony Stimulating Factors)), Drug (Pegfilgrastim, Tbo-filgrastim, Sargramostim, Filgrastim), Application (Aplastic Anemia, Bone Marrow Transplantation, Neutropenia, Neutropenia Associated with Chemotherapy, Neutropenia Associated with Radiation, Peripheral Progenitor Cell Transplantation), Dosage (Tablets, Capsule, Injection, Others), Route of Administration (Intravenous, Subcutaneous, Oral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America
|
|
Market Players Covered
|
Intas Pharmaceuticals Ltd. (India), Sanofi (France), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Biocon (India), Dr. Reddy’s Laboratories Ltd. (India), Amgen Inc. (U.S.), Merck KGaA (Germany), Takeda Pharmaceutical Company Limited (Japan), Thermo Fisher Scientific Inc. (U.S.), STADA Arzneimittel AG (Germany), Emcure Pharmaceuticals Limited. (India), CELLTRION INC. (South Korea), BIOCAD (Russia), Coherus BioSciences (US), Johnson & Johnson Private Limited (U.S.), Eli Lilly and Company (U.S.), and Abbott (U.S.)
|
|
Market Opportunities
|
|
Market Definition
In response to infection, colony stimulating factors are glycoproteins that encourage the development of white blood cells (mostly granulocytes such as neutrophils). Exogenous colony stimulating substances encourage stem cells in the bone marrow to create more of a certain type of white blood cell. The new white blood cells enter the bloodstream and begin fighting the illness. Patients who are receiving cancer treatment that induces low white blood cell counts (neutropenia) and puts them at risk of infection are given colony stimulating agents. Patients that get colony stimulating substances spend less time neutropenic.
Global Colony stimulating factors Market Dynamics
Drivers
- Increasing prevalence of hematological disorders
The prevalence of hematological disorders, such as leukemia and anemia, has been on the rise globally. Colony Stimulating Factors are used in the treatment of these conditions to stimulate the production of blood cells. The increasing incidence of such disorders is a significant driver for the colony stimulating factors market.
- Growing aging population
As the global population continues to age, there is an increased demand for therapies that can address age-related conditions, including those related to the hematopoietic system. This demographic shift has contributed to the growth of the colony stimulating factors market, as elderly individuals are more prone to hematological disorders.
- Advancements in biotechnology and healthcare
Advances in biotechnology, including the development of biosimilars, have played a pivotal role in the colony stimulating factors market's expansion. Biosimilars offer more cost-effective options for colony stimulating factors therapy, making them more accessible to a broader patient base.
- Growing investment for healthcare facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
- Expansion of emerging markets
Emerging markets, especially in Asia and Latin America, have shown a growing demand for healthcare services. The increasing awareness of colony stimulating factors and their potential in treating hematological disorders in these regions presents a significant growth opportunity for global Colony Stimulating Factors manufacturers.
- Development of Novel Colony Stimulating Factors Therapies
Research and development in the field of biotechnology and immunology can lead to the development of novel colony stimulating factors therapies. Innovations such as longer-acting colony stimulating factors, personalized medicine approaches, or new delivery methods can open up new avenues in the market and improve patient outcomes.
Restraints
- High treatment costs
Colony stimulating factors therapies can be expensive, which may limit access to these treatments for some patients, especially in regions with limited healthcare resources. The high cost of colony stimulating factors can be a significant restraint on market growth.
- Stringent regulatory requirements
Stringent regulatory requirements for the approval of new colony stimulating factors products can be a restraint. Companies face hurdles in navigating complex and evolving regulatory pathways, leading to delays in product launches and increased development costs.
Challenges
- Potential adverse effects
Colony stimulating factors therapy can have side effects, including bone pain, fever, and allergic reactions. These adverse effects can limit the use of colony stimulating factors in certain patient populations, and concerns about safety and tolerability can be a challenge for market expansion.
- Limited awareness and access
In some regions, there may be limited awareness about colony stimulating factors therapies, leading to underdiagnosis and undertreatment of hematological disorders. Additionally, unequal access to healthcare resources can hinder patient access to colony stimulating factors treatments, creating challenges for market growth.
This colony stimulating factors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the colony stimulating factors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In March 2023, Coherus BioSciences received U.S. FDA approval for its pegfilgrastim-cbqv (Udencya), a pegfilgrastim biosimilar for managing febrile neutropenia induced by chemotherapy.
- In September 2022, Spectrum Pharmaceuticals, Inc. received U.S. FDA approval for its ROLVEDON (eflapegrastim-xnst) injection, which is intended to decrease the incidence of infection, as manifested by febrile neutropenia in adult patients with non-myeloid-malignancies-receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Global Colony stimulating factors Market Scope
The colony stimulating factors market is segmented on the basis of type, drug, application, dosage, route of administration, end-users and distribution channel analysis. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Macrophage–Colony-Stimulating Factor (M-CSF)
- Multiple-Colony-Stimulating Factor, or Interleukin 3 (IL-3)
- Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF)
- Granulocyte–Colony-Stimulating Factor (G-CSF)
Drug
- Pegfilgrastim
- Tbo-filgrastim
- Sargramostim
- Filgrastim
Application
- Aplastic Anemia
- Bone Marrow Transplantation
- Neutropenia
- Neutropenia Associated with Chemotherapy
- Neutropenia Associated with Radiation
- Peripheral Progenitor Cell Transplantation
Dosage
- Injection
- Tablets
- Capsule
- Others
Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Colony stimulating factors Market Regional Analysis/Insights
The colony stimulating factors market is analysed and market size insights and trends are provided by country, type, drug, application, dosage, route of administration, end-users and distribution channel analysis as referenced above.
The countries covered in the colony stimulating factors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the colony stimulating factors market because of the rising prevalence of cancer in this region. Additionally, the growing presence of major key players and well-established healthcare infrastructure will further propel the market’s growth rate.
Asia-Pacific region is expected to grow during the forecast period of 2022-2029 due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The colony stimulating factors market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for colony stimulating factors market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the colony stimulating factors market. The data is available for historic period 2010-2020.
Competitive Landscape and Colony stimulating factors Market Share Analysis
The colony stimulating factors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to colony stimulating factors market.
Some of the major players operating in the colony stimulating factors market are:
- Intas Pharmaceuticals Ltd. (India)
- Sanofi (France)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Biocon (India)
- Dr. Reddy’s Laboratories Ltd. (India)
- Amgen Inc. (U.S.)
- Merck KGaA (Germany)
- Takeda Pharmaceutical Company Limited (Japan)
- Thermo Fisher Scientific Inc. (U.S.)
- STADA Arzneimittel AG (Germany)
- Emcure Pharmaceuticals Limited. (India)
- CELLTRION INC. (South Korea)
- BIOCAD (Russia)
- Coherus BioSciences (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Eli Lilly and Company (U.S.)
- Abbott (U.S.)
SKU-